Here's Why Arbutus Biopharma Corp. Stock Soared Today
Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) rode some mighty coattails today. This morning, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced highly positive data for a candidate that employs delivery technology it licensed from Arbutus. The surprisingly positive results raised hopes for future royalties and lifted the stock 20.7% higher to end Wednesday's session.
Alnylam suffered some safety-related setbacks that forced it to shutter a program with a drug similar to the candidate that succeeded today, patisiran. The familial amyloid polyneuropathy candidate uses Arbutus' lipid nanoparticle delivery technology to enter cells. If approved, Arbutus will be entitled to a single-digit royalty percentage on sales of the drug.
Image source: Getty Images.
Source: Fool.com
Alnylam Pharmace. Aktie
Starke Kaufsignale für Alnylam Pharmace.: Keine Sell-Einschätzungen, nur Buy-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für Alnylam Pharmace. mit einem Kursziel von 251 € im Vergleich zum aktuellen Kurs von 216.2 €.
